To read the full story, subscribe or sign in.

T3 Pharma closes $27M series C for live bacteria cancer immunotherapy

July 22, 2020

LONDON – Swiss startup T3 Pharma AG has raised CHF25 million (US$26.7 million) in a series C round, to fund a 100-patient phase I/II study of its live bacteria cancer immunotherapy.

BioWorld Immunotherapy Cancer Immuno-oncology Series C

Today's news in brief

BioWorld

BioWorld briefs for Feb. 27, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 27, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Clots and metastasis in cancer patients start in the lung

BioWorld MedTech

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...

Evo 2 AI allows genome and epigenome modeling of all life domains

BioWorld MedTech

A new version of Evo, the AI developed at the Arc Institute that can be used to design genomes as long as that of a bacterium, has been retrained with the DNA...